SCCA1 Inhibitors
Inhibitors of SCCA1, as detailed above, act indirectly due to the nature of SCCA1's role in cellular processes and its involvement in cancer pathology. SCCA1, as a serpin, is involved in regulating protease activity, affecting processes like apoptosis and cell survival, which are critical in the context of cancer. The chemicals listed here target various pathways and processes that can indirectly influence SCCA1's activity or its expression in cancer cells. Histone deacetylase inhibitors like Belinostat and Vorinostat can alter gene expression patterns, impacting SCCA1's expression. By modifying the chromatin structure, these compounds can influence the transcription of genes, including those involved in cancer progression and serpin regulation.
Proteasome inhibitors such as Bortezomib affect protein degradation pathways, which could have an indirect impact on SCCA1 levels or function. Bortezomib's ability to induce cellular stress and apoptosis might also influence the expression or role of SCCA1 in cancer cells. Tyrosine kinase inhibitors (Sorafenib, Sunitinib) and agents like Paclitaxel, 5-Fluorouracil, Gemcitabine, and Cisplatin can indirectly impact SCCA1 by affecting signaling pathways and cellular processes that are crucial in cancer development and progression
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat, a histone deacetylase inhibitor, may indirectly affect SCCA1 expression by altering epigenetic regulation of gene expression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, another histone deacetylase inhibitor, could influence SCCA1 expression through changes in chromatin structure and gene expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, may impact SCCA1 by affecting protein degradation pathways and cellular stress responses. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a kinase inhibitor, could indirectly affect SCCA1 through its effects on cell signaling pathways involved in cancer progression. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, targeting multiple tyrosine kinases, may influence SCCA1 expression or activity by modulating signaling pathways in cancer cells. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel, a microtubule stabilizer, might indirectly impact SCCA1 expression or function through its effects on cell division and apoptosis. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus, an mTOR inhibitor, could influence SCCA1 by altering pathways related to cell growth and survival. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
5-Fluorouracil, an antimetabolite chemotherapeutic agent, may affect SCCA1 indirectly through its role in DNA synthesis and repair. | ||||||
Gemcitabine Hydrochloride | 122111-03-9 | sc-204763 sc-204763A | 25 mg 100 mg | $96.00 $289.00 | 13 | |
Gemcitabine, a nucleoside analog, could impact SCCA1 expression or activity as part of its broader effects on DNA replication and cell proliferation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin, a platinum-based chemotherapeutic, might influence SCCA1 indirectly through its impact on DNA damage and cellular stress pathways. | ||||||